Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsClindamycin150-600 mg PO TID or 600mg IV Q8HAdminister Anytime During HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
425102-43-560-950.6-1.2N/A0 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Cimino, J. E., & Tierno, P. M. (1969). Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Applied microbiology, 17(3), 446-8. Retrieved from
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:
  • Eastwood, J. B., & Sc, B. (1974). A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure. Postgraduate Medical Journal, (November), 710-712.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Roberts A, Eastwood J, Gower P, Fenton C, Curtis J. Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects. European journal of clinical pharmacology 1978; 14(6), 435-9.